

# INTERNATIONAL HEALTHWAY CORPORATION LIMITED

Registration No.: 201304341E  
(Incorporated in the Republic of Singapore)

---

## ISSUE OF S\$50,000,000 7.00 PER CENT. NOTES DUE 2017 UNDER THE S\$500,000,000 MULTICURRENCY MEDIUM TERM NOTE PROGRAMME OF INTERNATIONAL HEALTHWAY CORPORATION LIMITED

---

Further to the announcement dated 20 April 2015, the board of directors (the **"Board"**) of International Healthway Corporation Limited (the **"Issuer"**) is pleased to announce that it has today issued S\$50,000,000 7.00 per cent. Notes due 2017 (the **"Series 2 Notes"**) under its S\$500,000,000 multicurrency medium term note programme (the **"Programme"**).

Oversea-Chinese Banking Corporation Limited acted as sole bookrunner and lead manager in connection with the Series 2 Notes.

The Series 2 Notes were issued at an issue price of 100 per cent. of their principal amount and in denominations of S\$250,000. The Series 2 Notes will bear interest at a fixed rate of 7.00 per cent. per annum payable semi-annually in arrear and will mature on 27 April 2017.

The Notes constitute direct, unconditional, unsubordinated and unsecured obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The net proceeds arising from the issue of the Series 2 Notes (after deducting issue expenses) will be used for the refinancing purposes of the Group.

Pursuant to Condition 5(e)(ii), a "Change of Shareholding Event" will occur when Fan Kow Hin, Aathar Ah Kong Andrew and Jong Hee Sen and their Immediate Family Members (as defined in the Conditions) cease to own in aggregate (whether directly or indirectly) at least 30 per cent. of the issued share capital of the Issuer. Upon the occurrence of a "Change of Shareholding Event", each holder of the Series 2 Notes has an option to require the Issuer to redeem the Series 2 Notes of such holder (subject to the Conditions).

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (the **"SGX-ST"**) for the listing and quotation of the Series 2 Notes on the SGX-ST. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 2 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries (if any), its associated companies (if any), its joint venture companies (if any), the Programme or the Series 2 Notes. The Series 2 Notes are expected to be listed on the SGX-ST on 28 April 2015.

Terms defined in the information memorandum dated 23 January 2015 in relation to the Programme shall have the same meaning in this announcement unless otherwise defined herein.

### BY ORDER OF THE BOARD

Chia Kwok Ping  
Chief Executive Officer and Executive Director  
27 April 2015

*International Healthway Corporation Limited (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 8 July 2013. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").*

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.*